BlogSeptember 27, 2022 Payton Nyquvest, CEO of Numinus, Sits in the Investor Hotseat on September 29th
PressSeptember 27, 2022 Tryp Therapeutics Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline Forms of TRP-8803
PressSeptember 26, 2022 Wellbeing Subsidiary KGK Science Opens New Clinical Research Center to Reimagine a Healthier Future
PressSeptember 24, 2022 Irwin Naturals Inc Announces Normal Course Issuer Bid for Subordinate Voting Shares of the Corporation
PressSeptember 24, 2022 Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada
PressSeptember 24, 2022 Core One Labs Signs Letter of Intent with GMP Manufacturing Partner for Production of Proprietary Psychedelic Compounds
PressSeptember 24, 2022 Mydecine Innovations Group Announces Closing Under Share Subscription Agreement and Welcomes New CFO
PressSeptember 22, 2022 Origin Therapeutics’ Portfolio Company, Xpira Pharmaceuticals, Receives FDA Approval For Psilocybin Trial IND Application
PressSeptember 22, 2022 Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives
PressSeptember 22, 2022 Ketamine Wellness Centers (KWC) Partners with Veterans Administration Community Care Network (VA-CCN) To Expand SPRAVATO® Coverage
PressSeptember 22, 2022 Numinus Expands Ketamine Therapy for Mental Health in Montreal and announces new brand awareness initiatives
BlogSeptember 21, 2022 Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program
BlogSeptember 21, 2022 Robbie Bent is Building the Future of Emotional Wellness – Podcast Episode #18
